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Abstract: Cellular uptake of therapeutic oligonucleotides and subsequent intracellular trafficking to their target sites rep-
resents the major technical hurdle for the biological effectiveness of these potential drugs. Accordingly, laboratories 
worldwide focus on the development of suitable delivery systems. Among the different available non-viral systems like 
cationic polymers, cationic liposomes and polymeric nanoparticles, cell-penetrating peptides (CPPs) represent an attrac-
tive concept to bypass the problem of poor membrane permeability of these charged macromolecules. While uptake per se 
in most cases does not represent the main obstacle of nucleic acid delivery in vitro, it becomes increasingly apparent that 
intracellular trafficking is the bottleneck. As a consequence, in order to optimize a given delivery system, a side-by-side 
analysis of nucleic acid cargo internalized and the corresponding biological effect is required to determine the overall effi-
cacy. In this review, we will concentrate on peptide-mediated delivery of siRNAs and steric block oligonucleotides and 
discuss different methods for quantitative assessment of the amount of cargo taken up and how to correlate those numbers 
with biological effects by applying easy to handle reporter systems. To illustrate current limitations of non-viral nucleic 
acid delivery systems, we present own data as an example and discuss options of how to enhance trafficking of molecules 
entrapped in cellular compartments.  
Key Words: Cell-Penetrating Peptides (CPPs), nucleic acid delivery, endocytosis, fluorescence microscopy, RNAi, siRNA, 
steric block, splice correction. 
INTRODUCTION 
  Oligonucleotide-based strategies which can be used to 
modulate a vast variety of cellular functions represent a 
promising alternative to conventional therapies (for a review 
see: [1,2]). Among the different oligonucleotides with thera-
peutic potential are aptamers, transcription factor-binding 
decoy oligonucleotides, ribozymes, triplex-forming oligonu-
cleotides (TFO), immunostimulatory CpG motifs, antisense 
oligonucleotides, small interfering RNAs (siRNAs) and an-
tagomirs. Nowadays, these potential macromolecular drugs 
are generally either relatively easily derived by rational de-
sign (e.g. antisense or siRNA) or straightforward selection 
processes (e.g. aptamers). One of their main advantages over 
protein- or peptide-based approaches comprises the high 
specificity for their target while being non-immunogenic. 
However, despite these advances, a major impediment to the 
development of nucleic acid-based strategies for treatment 
and prevention of diseases is the relatively inefficient means 
to effectively deliver these macromolecules into the desired 
target cells. Although viral vectors have been widely used to 
transfer genetic material into cells [3,4], they bear an inher-
ent risk for the patient to encounter severe immunological 
responses or even develop cancer [5-8]. As a result of these 
problems much attention has been paid in recent years to the 
development of non-viral delivery systems. This conception  
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includes an assortment of fairly unrelated approaches yield-
ing various degrees of enhanced cellular uptake of nucleic 
acids. Currently, liposomes and cationic polymers are used 
as a standard tool to transfect cells in vitro. However, these 
procedures are characterized by a significant lack of effi-
ciency accompanied by a high level of toxicity rendering 
them mostly inadequate for in vivo applications. In this con-
text cell-penetrating peptides (see below) represent an inter-
esting alternative as they generally are less toxic than 
liposomes or cationic polymers. Moreover, they are com-
monly better suited to transfer cargo into different cell types 
like non-adherent cells and primary cells, which are hard to 
transfect using commercially available standard protocols. 
The most advanced approaches in the field, which are not 
subject of the present article, are complex carrier systems 
combining vantages of assorted strategies to generate 
nanoparticles with better defined properties aimed towards 
enhanced uptake as well as intracellular trafficking in com-
bination with cell-specific functionalities. For example, there 
are attempts to combine peptides with cationic liposomes [9-
16] or polyethyleneimine (PEI) [17]. Other strategies are 
aimed towards the synthesis of high or low molecular weight 
branched polymers and/or peptides [18-22] or dendrimers 
[23,24]. Even more complex systems are particularly prom-
ising with respect to in vivo delivery [25-29]. 
  In this review we will report about particular aspects of 
non-viral oligonucleotide delivery in vitro, pinpointing the 
current limitations, and provide quantitative means for de-
termining where the bottlenecks of such strategies at present  
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are. The focus of this article is recent progress in the field of 
peptide-mediated cellular delivery of siRNA and steric block 
oligonucleotides in cell tissue culture as a starting point for 
further developments illustrated by own experimental data. 
Our intention is not to provide the reader with easy solutions 
on how to solve the existing problems encountered with such 
approaches but give some hints where to start optimizing a 
particular approach.  
CELL-PENETRATING PEPTIDES 
  The idea of using peptides as carriers goes back some 
twenty years when it was discovered that the HIV-1 transac-
tivating protein Tat is taken up by mammalian cells [30,31]. 
A few years later, the Antennapedia homeodomain of Dro-
sophila melanogaster was shown to act similarly [32]. Later 
on, it could be shown that peptides derived from Tat and 
Antennapedia as well as other proteins are capable of trans-
porting macromolecular cargo molecules into cells [33-35]. 
Based on such promising results, a rapidly expanding field 
focusing on the so-called cell-penetrating peptides (CPPs), 
also referred to as protein transduction domains (PTD), be-
gan to develop. Since the first reports about Tat, a large 
number of naturally occurring as well as engineered CPPs 
have been discovered [36-42]. Table 1 gives an overview of 
selected “classical” CPPs. Generally, CPPs are short polyca-
tionic sequences of less than 30 amino acids that are able to 
translocate different cargoes (e.g. nucleic acids, peptides and 
even entire proteins) into cells. The only common character-
istic of these peptides appears to be that they are amphipathic 
and net positively charged at physiological pH. Frequently 
the cargo is covalently attached to the CPP which can be 
achieved by expression as a fusion construct or by chemical 
coupling (for a review see: [43]). In particular cases, cargo 
and carrier bind each other non-covalently through mainly 
ionic interactions [40,44,45]. 
  Despite the widespread interest in peptide carriers, the 
mechanisms underlying the cellular translocation of CPPs 
are poorly understood. Early work relied upon fluorescence 
imaging or flow cytometry analysis of chemically fixed cells 
to examine intracellular localization of fluorescently labeled 
peptides in the absence or presence of cargo. According to 
these experiments peptides appeared to be internalized very 
rapidly within minutes even at 4 °C. From such observations 
it was concluded that CPPs penetrate cell membranes by an 
energy-independent mechanism [46-50]. Although it had 
been reported quite early on that certain fixation procedures 
may cause artefacts leading to an overestimation of the cellu-
lar uptake rates [51-53] the dimension of this problem was 
not commonly recognized until a side by side comparison of 
fixed and living cells was published [54]. Based on these 
findings, many groups re-examined their data. However, 
despite considerable technical improvements, there are still 
puzzling controversial results concerning the exact mecha-
nism of CPP uptake. Though in most cases endocytosis has 
been suggested to be the main route of internalization (Fig. 
(1A)), substantial difficulties are encountered identifying the 
exact pathway ([42,55] and references therein). Prior to en-
docytosis CPPs interact electrostatically with the extracellu-
lar matrix of the cell surface mostly through binding to nega-
tively charged glycosaminoglycans, i.e. heparan sulfate pro-
teoglycans [56-59]. Recent studies indicate that the uptake 
mechanism of CPPs can be influenced by the attachment of 
cargos. For example, Richard et al. [54,60] reported a colo-
calization of Tat
48-59 with markers of clathrin-mediated en-
docytosis, whereas Fittipaldi et al. [61] found a caveo-
lae/lipid raft-dependent process for a Tat-GFP fusion protein 
and Wadia et al. [62] described a macropinocytotic uptake 
pathway for a fusion construct of Tat peptide with Cre re-
combinase. In summary, the precise mechanism of internali-
zation remains elusive and strongly depends on the proper-
ties of both CPP and cargo as well as on the transfection 
conditions and the cell lines used [63-68].  
  As opposed to the majority of CPP applications reported, 
which rely on covalent linkage of carrier and cargo, limiting 
their general use considerably as a new construct has to be 
generated as well as tested for any given nucleic acid cargo, 
we will focus in this article on a peptide termed MPG 
which forms highly stable non-covalent complexes with nu-
cleic acids (Fig. (1)). The peptide is a derivative of the origi-
nal MPG peptide described by Morris and coworkers [47] 
and differs by five amino acids in the hydrophobic part. 
These changes result in an alteration of the overall structure 
of the peptide towards a higher tendency of adopting a heli-
cal conformation [69]. Accordingly, the two peptides behave 
Table 1.  Sequences of Selected “Classical” CPPs 
Peptide Sequence  References 
Tat
48-60 GRKKRRQRRRPPQ  [48] 
penetratin (Antp
43-58) RQIKIWFQNRRMKWKK   [203] 
transportan   GWTLNSAGYLLGKINLKALAALAKKIL   [204] 
TP10   AGYLLGKINLKALAALAKKIL   [205] 
Oligoarginine (R8) RRRRRRRR    [50] 
MAP KLALKLALKALKAALKLA    [163] 
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV    [47] 
MPG GALFLAFLAAALSLMGLWSQPKKKRKV  [69] Peptide-Mediated Cellular Delivery of Oligonucleotide-Based Therapeutics  Current Pharmaceutical Design, 2008, Vol. 14, No. 34    3639 
differently with respect to their interaction with artificial 
lipids as well as Xenopus oocytes [70,71] and most probably, 
their exact mechanism of uptake is not the same. Besides 
ionic interactions responsible for the initial peptide/nucleic 
acid complex formation, hydrophobic peptide/peptide inter-
actions drive the maturation of large nanoparticles in a 
sandwich-like assembly reaction (Fig. (1B) and Fig. (2)). 
MECHANISM OF RNA INTERFERENCE 
  In recent years, RNA interference (RNAi) has gained a 
lot of interest as a tool for functional genomics studies and 
probably equally important as a promising therapeutic ap-
proach for the treatment of various diseases [72,73]. RNAi is 
a highly evolutionally conserved and specific process of 
post-transcriptional gene silencing (PTGS) by which double 
stranded RNA (dsRNA), when introduced into a cell, causes 
sequence-specific degradation of homologous mRNA se-
quences [74,75]. Mechanistically the process can be divided 
into two steps. An initiator step where dsRNA is cleaved by 
dicer, a member of the RNase III family, into 21-25 nt long 
small interfering RNA (siRNA) fragments [76]. In a con-
secutive step, these fragments are transferred to RISC (RNA-
induced silencing complex) where one of the strands, the so 
called guide strand, serves as a molecular template to recog-
nize homologous mRNA that is cleaved by Argonaute 
[77,78], a protein component of RISC. Once the guide strand 
is bound to RISC this complex can undergo many rounds of 
mRNA binding and cleavage ([79], Fig. (3A)). To circum-
vent application of long double stranded RNAs, which inevi-
tably trigger an interferon response, it is sufficient to ex-
tracellularly supply 21 nt long dsRNAs [80,81]. Alterna-
tively, siRNAs can be expressed endogenously using DNA 
vectors which code for short hairpin (sh) RNAs [82-84]. 
These shRNAs are than cleaved by dicer to siRNAs. Short 
hairpin RNA constructs have advantages over siRNA be-
cause the effects of these constructs can lead to a more stable 
and long-term result. On the other hand, besides the fact that 
shRNAs might interfere with the microRNA pathway 
[85,86], this strategy requires a gene therapy approach in the 
long run [87]. For this reason we will not cover shRNAs. 
LITERATURE OVERVIEW: CPP-MEDIATED siRNA 
DELIVERY 
  As described above, siRNAs represent a valuable tool to 
inhibit the expression of a target gene in a sequence-specific 
manner. In the following section, selected examples of CPP-
mediated siRNA delivery will be presented which are sum-
marized in Table 2. Only a few studies describe the covalent 
attachment of nucleic acid cargo and peptide carrier (confer 
Table 2). In one approach, simple mixing of siRNA targeted 
against GFP or CDK9 and Tat peptide did not generate any 
measurable RNAi effect whereas cross-linked siRNA-Tat
47-
57 led to a significant down-regulation of the target proteins. 
However, high concentrations of siRNA (about 300 nM) had 
to be used [88]. Both LF- and Tat
47-57-mediated transfections 
resulted in a perinuclear localization of siRNA. In contrast, 
fluorescently labeled Tat
47-57 without cargo was mainly 
found in the nucleolus, suggesting that interactions with 
RISC influence subcellular localization. In another approach, 
significant uptake of siRNAs targeted against luciferase or 
GFP could be observed after disulfide coupling the 5’-end of 
the sense strand to penetratin or transportan [89]. Compared 
to LF2000, slightly higher levels of transfection were 
achieved. Interestingly, after LF2000-mediated transfection, 
basal luciferase activity returned to normal levels one day 
earlier than after CPP-mediated transfection although the 
same concentration of siRNA was applied. A remarkably 
strong RNAi effect in hard to transfect primary neuronal 
cells was reported by Davidson et al. [90]. Here, siRNAs 
directed against several endogenous proteins were coupled to 
penetratin via a disulfide bond. The observed down regula-
tion of the target proteins after peptide-mediated siRNA de-
livery was found to be far more effective compared to 
LF2000. This was in part attributed to the toxicity of the lip-
ids. As one of the first groups to report on Tat
48-60- or pene-
tratin-mediated siRNA delivery in vivo, Moschos et al. 
showed, that intratracheal administration of the conjugates 
did not lead to any intensification of the knockdown of the 
target gene p38 mitogen-activated protein kinase in mouse 
lungs in comparison to unmodified non-formulated siRNA 
[91]. Strikingly, it was found that the peptides alone trig-
gered a detectable decrease in target gene expression and that 
the penetratin-conjugate induced elevated levels of the im-
mune markers IFN-, TNF-, and IL-12p40 in lung tissue.  
  Besides technical difficulties arising from the syntheses 
of conjugates consisting of short cationic or hydrophobic 
peptides and highly negatively charged siRNAs, Dowdy and 
his group [92] present a rather critical point of view referring 
to previous studies with CPP-siRNA-conjugates. They claim 
that the successful delivery described therein is solely the 
result of excess free peptide, which leads to additional com-
plexation, and thereby cellular import of the siRNA. This is 
in accordance with Turner et al. [93], who were the first to 
observe that careful purification of CPP-antisense-conjugates 
abrogates their biological effect. Among other things, this 
might be the reason why most of the studies reporting on 
successful peptide-mediated delivery of siRNAs use a non-
covalent complexation approach (confer Table 2).  
  In 2003, Simeoni et al. [94] were the first who non-
covalently complexed siRNA with the peptide MPG. At a 
1:10 ratio of negative nucleic acid to positive peptide 
charges a decrease in luciferase activity of about 80 % was 
detectable in HeLa or Cos-7 cells. This effect was further 
enhanced to about 90 % down-regulation by a mutation in 
the NLS sequence of the carrier peptide (MPG
NLS), pre-
sumably due to an increased delivery to the cytoplasm, where 
RISC is localized. Recently, Veldhoen et al. [55] used a deri- 
vative of the MPG peptide for the delivery of siRNA, which 
will be described in the chapter “MPG-mediated delivery 
of siRNA and steric block oligonucleotides”. Leng et al. [21] 
presented promising results with a prospect for cell-specific 
siRNA delivery. Different versions of a branched histidine/ 
lysine-polymer (H3K8b) yielded up to 80 % knockdown of 
the target gene in several cell types. Structure-function stud-
ies revealed an important role of the composition of the his-
tidine-rich domain as well as its position within the peptide 
and the branches for siRNA delivery, whereas size and sur-
face charge did not have any effect. Furthermore, the toxicity 
was much lower than for the commercial cationic lipids Oli-
gofectamine and LF2000. Finally, the attachment of the 
tripeptide RGD, an integrin-ligand, slightly enhanced siRNA 
delivery and turned this carrier into a cell-specific system. A 3640    Current Pharmaceutical Design, 2008, Vol. 14, No. 34  Laufer and Restle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Simplistic scheme of peptide-based nucleic acid delivery systems (A). Interaction of CPP and cargo is either achieved by covalent 
attachment or by non-covalent complexation through mainly ionic interactions. In case of non-covalent complex formation, a further assem-
bly of cargo/carrier complexes occurs, leading to the formation of large nanoparticles (confer Fig. (2)). In case of covalently joined molecules 
a similar scenario is less likely, yet cannot be excluded. Prior to the translocation process the particles attach to the cell surface by ionic inter-
actions of positively charged CPP residues with negatively charged membrane components. Subsequently, complexes are taken up via an 
endocytotic pathway. Although less likely, direct penetration cannot be excluded and may occur simultaneously. Once inside the cell, the 
cargo has to escape from vesicular compartments, otherwise it eventually gets degraded in the lysosome. Red: negative charges, blue: positive 
charges, green: hydrophobic domains. 
Three-dimensional model of MPG/siRNA interactions (B). The model was generated by iterative rigid body docking cycles of siRNA 
(PDB 1R9F) and peptide using the program Hex 4.2 [201]. The PDB file of MPG was generated with the program ICM (Molsoft LLC) tak-
ing into consideration different secondary structure predictions and energy minimization protocols. Out of many docking solutions particular 
ones were picked for illustration purposes using the program Chimera [202]. The phosphate backbone of the siRNA is shown in red, the nu-
cleobases in light gray. Aliphatic, aromatic and hydrophobic residues of the peptide are shown in green, positive charged residues in blue and 
the remaining amino acids in gray. It is assumed that formation of larger particles is driven by hydrophobic peptide/peptide interactions gen-
erating free positive charges where other siRNA molecules can interact. This eventually drives complex formation in a sandwich or mesh like 
assembly reaction. In principle such a scenario holds true for any given nucleic acid cargo.  Peptide-Mediated Cellular Delivery of Oligonucleotide-Based Therapeutics  Current Pharmaceutical Design, 2008, Vol. 14, No. 34    3641 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Dynamic light scattering measurements of MPG/ 
siRNA complexes. Experiments were performed with 5 M pep-
tide and 0.5 M siRNA in a Tris-buffered (10 mM, pH 7.5) aque-
ous solution at 20°C using a DynaPro MS/X device (Protein Solu-
tions, UK). Depending on buffer composition (e.g. ionic strength), 
complexes which range in size between 20 and 300 nm with an 
average of about 200 nm are observed. 
similar concept has very recently been used by Kumar et al. 
[95] for a specific delivery approach into the brain. A peptide 
derived from rabies virus glycoprotein (RVG) interacts spe-
cifically with the nicotinic acetylcholine receptor (AchR) on 
neuronal cells to enable viral entry. The authors could show 
that the biotinylated form of the 29-amino-acid peptide 
(YTIWMPENPRPGTPCDIFTNSRGKRASNG) was taken 
up by neuronal cells. In order to transport nucleic acids with 
this vehicle, R9 was conjugated to RVG peptide. Systemic 
treatment of mice with siRNA in a non-covalent complex 
with this modified peptide promoted a highly specific cellu-
lar import of siRNA only into cells expressing AchR. Even 
more important, an antiviral siRNA treatment resulted in 
successful protection of mice against encephalitis caused by 
Japanese encephalitis virus (JEV). This is the first study to 
report on a non-toxic method to deliver siRNA across the 
blood brain barrier which could help to circumvent danger-
ous and ineffective injections into the brain. To date it pre-
sents one of the most promising tissue-specific delivery ap-
proaches which might be expandable to other in vivo applica-
tions.  
  Along these lines, most studies today are performed with 
the aim of CPP-mediated siRNA delivery in vivo. Although 
many of them are already showing promising results, e.g. 
concerning tumor-targeting and ocular delivery [96-98], this 
is beyond the scope of this review and will be discussed 
elsewhere in this issue [99,100].  
  With the aim to increase the endosomal escape of siR-
NAs after peptide-mediated delivery, Lundberg et al. [101] 
rationally modified penetratin to form a CPP (termed EB1) 
with improved endosomolytic properties. They achieved a 
pH-dependent conformational change of the peptide to a 
higher degree of helicity by the replacement of two basic 
amino acids with histidines and the N-terminal addition of 
six amino acids. In this study, several CPPs were compared 
in a non-covalent approach by measuring the overall cellular 
Table 2.  Examples for Peptide-Mediated Delivery of siRNA 
CPP/Delivery System 
Mode of 
Linkage* 
Target Cell  Line  Ref. 
Tat
47-57, Tat-derived oligocarbamate)  c  EGFP, CDK9  HeLa  [88] 
penetratin, transportan   c  luciferase, GFP  Cos-7, C166, EOMA, CHO-AA8  [89] 
penetratin   c  Cu-ZN SOD-1, Caspase-3/-8/-9  primary rat hippocampal or sympathetic neurons  [90] 
Tat
48–60, penetratin   c  p38 MAP kinase  L929 (mouse fibroblasts), mouse lung (intratracheal)  [91] 
MPG, MPG
NLS   n-c  luciferase, GAPDH  HeLa, Cos-7, HS-68  [94] 
H3K8b, H3K8b(+RGD)   n-c  -Gal, luciferase  SVR-bag4, MDA-MB-435, C6  [21] 
RVG-9R   n-c  GFP, Cu-ZN SOD-1, JEV  HeLa, Neuro2a, mouse brain (intravenously)  [95] 
POD n-c  EGFP  HER  911  [96] 
Chol-R9  n-c  VEGF  CT-26, mouse (intratumoral)  [97] 
EB1, MPG
NLS, bPrPp   n-c  luciferase  HeLa, HepG2  [101] 
TatU1A  n-c  EGFP, EGFR  CHO, A431,   [104] 
MPG   n-c  luciferase  HeLa, ECV 304  [55] 
rCPP n-c  EGFP,  EF1A  HeLa,  H1299 [29] 
stearyl-R8   n-c  EGFP, MAP2B  primary rat hippocampal neurons  [206] 
R8-MEND (siRNA/stearyl-R8 core)   n-c  luciferase  HeLa  [207] 
* c = covalent / n-c = non-covalent. 3642    Current Pharmaceutical Design, 2008, Vol. 14, No. 34  Laufer and Restle 
uptake via fluorescence and biological effect of siRNA tar-
geted to luciferase mRNA. Penetratin- as well as TP10-
mediated transfection did not lead to any silencing of lu-
ciferase gene expression, despite high amounts of intracellu-
lar siRNA [101] and in contrast to previous reports using 
siRNA-penetratin-conjugates [90] or TP10/DNA-complexes 
[102]. EB1-mediated delivery of 100 nM siRNA led to ap-
proximately 50 % reduction of luciferase activity. This si-
lencing effect was slightly better than for bPrPp and in the 
same range as for MPG
NLS, but still not as pronounced as 
for LF2000-mediated transfection of 100 nM siRNA. As it 
was described earlier, that addition of a pH-sensitive peptide 
derived from hemagglutinin (HA2) can promote endosomal 
escape [62], the authors linked HA2 to penetratin [101]. It 
turned out that although HA2-penetratin improved the si-
lencing effect when coincubated with penetratin, EB1 was 
more potent than this combination of peptides. Together with 
confocal microscopy studies the authors concluded that the 
lack of biological effect after penetratin-mediated siRNA 
delivery is due to a lack of endosomal escape and that EB1 
has a superior endosomolytic activity in comparison to HA2-
penetratin.  
 Endoh  et al. [103,104] very recently presented an innova-
tive strategy, called CLIP-RNAi (i.e. CPP-linked RBP-
mediated RNA internalization and photo-induced RNAi) 
combining delivery of a specific RNA sequence with enhan-
ced photoinduced release of RNA from endosomes. This 
goal was accomplished by fusing the U1A RNA-binding 
domain (RBD) to the Tat peptide and extending the siRNA 
with a short stretch of nucleotides specifically recognized by 
this RBD. These complexes were efficiently internalized but 
exhibited a punctuate cytoplasmic localization pattern, in-
dicative of endosomal entrapment. However, photostimula-
tion of a fluorophore attached to the peptide led to a redistri-
bution of complex into the cytosol followed by efficient 
RNAi-mediated gene silencing.  
MECHANISMS OF ALTERNATIVE SPLICING 
  Human pre-mRNAs contain on average eight expressed 
sequences (exons) with an average length of 150 nt and up to 
60 intervening sequences (introns) which can vary in length 
between 35 and 10,000 nt, therefore comprising up to 90 % 
of each transcriptional unit. In the nucleus, ribonucleoprotein 
complexes called spliceosomes recognize exon-intron boun- 
daries and catalyze the precise removal of introns and subse-
quent joining of exons in a process called RNA splicing 
[105-107]. Additionally, each primary transcript can yield 
different mature RNAs through alternative splicing, thereby 
expanding the information content and versatility of the tran-
scriptome, e.g. through the production of protein isoforms. A 
recent study of 10,000 human genes revealed, that at least 70 
% of all multi-exon genes are alternatively spliced [108]. 
There are several different types of alternative splicing, 
amongst others affecting transcription start sites, splice sites, 
polyadenylation sites or even whole introns and exons. Dis-
ruptions of these intricate splicing patterns are tightly cou-
pled with human pathophysiology, either as a determinant or 
a direct cause of disease or as a modifier of disease suscepti-
bility and severity [109]. Among these diseases are -thala- 
ssemia, cystic fibrosis, muscular dystrophies, Frasier syn-
drome, certain kinds of dementia and cancer. A more de-
tailed description of the underlying mechanisms is beyond 
the focus of this article and can be found in a number of re-
views [110-113]. López-Bigas et al. [114] proposed that 60 
% of mutations that cause disease lead to splicing defects 
rather than changes in the amino acid sequence. Two com-
mon forms of mutations are depicted in Fig. (3B). On the 
one hand, a mutation in the splice donor can favor recogni-
tion of a cryptic splice donor and result in a mutant mRNA 
containing additional intronic sequences (part I). On the 
other hand, a mutation in the splice acceptor can lead to 
skipping of a whole exon and result in a shortened mRNA 
(part II). Both scenarios have been used in the context of 
antisense oligonucleotide-mediated approaches targeting 
alternative splicing. The use of antisense oligonucleotides 
interacting with mRNA to affect protein production goes 
back some 20 years [115,116]. Since then, three principle 
mechanisms have been exploited for this purpose (for a re-
view see: [117,118]): (I) the oligonucleotide/RNA duplex 
forms a substrate for endogenous RNase H, leading to 
mRNA cleavage; (II) the oligonucleotide/RNA duplex pre-
vents the productive assembly of the ribosomal complex or 
arrests a ribosomal complex already engaged in translation, 
in both cases affecting protein biosynthesis; (III) the oli-
gonucleotide/RNA duplex alters pre-mRNA splicing in the 
nucleus. The following section will focus on the last ap-
proach with the aim to treat splicing disorders and give ex-
amples of possible applications for CPPs in this context.  
LITERATURE OVERVIEW: CPP-MEDIATED STERIC 
BLOCK OLIGONUCLEOTIDE DELIVERY 
  Different forms of human -thalassemia are caused by 
mutations within in the -globin intron 2, which activate 
cryptic splice sites and thus lead to the formation of non-
functional transcripts (Fig. (3B part I)). Those aberrantly 
used sites can be blocked by antisense steric block oligonu-
cleotides, which leads to the synthesis of functional protein 
[119,120]. Kole and his group adopted this principle for the 
development of a splice correction assay [121]. In this model 
system, a firefly luciferase construct leads to the synthesis of 
inactive enzyme because the reporter gene pre-mRNA is 
interrupted by the human -globin intron 2 containing an 
aberrant splice site. Upon binding of a steric block oligonu-
cleotide, correct splicing is restored which in turn yields a 
functional luciferase protein. To achieve this, the oligonu-
cleotide has to be delivered to the nucleus. Furthermore, only 
oligonucleotides that don’t activate RNase H are applicable 
[2], e.g. phosphorodiamidate morpholino oligomers (PMO, 
[122]), locked nucleic acids (LNA, [123]), peptide nucleic 
acids (PNA, [124]) or 2’-O-methyl-modified oligonucleo-
tides (OMe). In addition to their inability to activate RNase 
H, most of these modifications confer higher affinity to the 
target RNA and increased resistance against enzymatic deg-
radation than unmodified versions. Compared to RNAi-
based model systems, this assay is less susceptible to side 
effects like cytotoxicity or off-target effects because the re-
porter gene activity is turned up rather than turned down. 
The splice correction assay has been successfully applied for 
the analysis of several carrier systems [24,93,125-135]. In 
the following section, selected examples will be presented, 
which are summarized in Table 3. In contrast to many non-
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splice correction was only achieved with conjugates of pep-
tide and steric block oligonucleotide. Astriab-Fisher et al. 
[128] described delivery of OMe RNA phosphorothioate 
oligonucleotides linked via a disulfide bridge to Tat peptide 
and penetratin. A few hours after transfection, the CPP-
oligonucleotide conjugates were detected both in cytoplas-
mic vesicles and in the nucleus and caused a dose-dependent 
increase in luciferase activity. These findings are in contrast 
to results of Turner et al. [93], who could not find a biologi-
cal effect for several CPP-oligonucleotide conjugates in a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Mechanistic principles of RNAi (A) and splice correction (B). Details are given in the text.  
 
Table 3.  Examples for Peptide-Mediated Delivery of Steric Block Oligonucleotides 
Oligonucleotide Cargo   CPP/Delivery System  Application  Ref. 
2’-OMe phosphorothioate RNA   Tat
49-60, penetratin   splice correction   [128] 
RNA analogues  Tat
48-58, penetratin, R6-penetratin, transportan, R9, R9F2 and further peptides  HIV-1 transactivation  [93] 
PMO   R9F2, Tat peptide, penetratin  splice correction  [136] 
PNA Tat
48-58, penetratin, transportan analogues, R9F2, R6-penetratin   HIV-1 transactivation  [137] 
PMO (R-Ahx-R)4 splice  correction  [126] 
PNA R6-penetratin splice  correction  [127] 
PMO (R-Ahx-R)4AhxB exon  skipping  [152] 
PMO R8-derivatives containing non- amino acids  exon skipping  [153] 
PNA  Tat, MSP, AAV6, AAV8  exon skipping  [154] 3644    Current Pharmaceutical Design, 2008, Vol. 14, No. 34  Laufer and Restle 
HeLa cell assay for Tat-mediated transactivation of the HIV-
1 long terminal repeat. The authors observed vesicular up-
take but no nuclear import for their highly pure conjugates. 
Interestingly, the rate of uptake could be enhanced by addi-
tion of free CPP to the conjugates, though still no biological 
activity was detected. Based on these findings, Turner et al. 
[93] concluded that these free CPPs form complexes with 
CPP-cargo conjugates, which play a significant role in the 
uptake process. This is in accordance with observations by 
Meade et al. [92] for the uptake of CPP-siRNA conjugates 
described above. Moulton et al. [136] achieved correction of 
missplicing at low micromolar concentrations of a R9F2-
PMO conjugate but not with complexes of peptide and PMO. 
The steric block activity of the R9F2-PMO conjugates could 
be further increased with longer spacers whereas variations 
in the conjugation chemistry did not result in any differ-
ences. Furthermore, transfection rates were higher than for 
conjugates with Tat peptide, penetratin or a Tat peptide ana-
logue. Using the HIV-1 transactivation assay mentioned 
above, Turner et al. [137] could show that most CPP-oligo- 
nucleotide conjugates attained biologic activity only through 
co-administration of the endosomolytic substance chloro-
quine. Fluorescence microscopy analyses revealed that this 
treatment released fluorescently labeled conjugates from 
endosomal compartments into the nucleus. Besides the addi-
tion of chloroquine, different endosome disrupting strategies 
have been evaluated using the splice correction assay, for 
example co-treatment with endosome-disruptive peptides 
[129] or photochemical internalization [138] (see chapter 
“Strategies to enhance endosomal escape”). However, the 
most promising results have been achieved with two newly 
developed derivatives of classical CPPs (reviewed in [130]). 
The modification of oligoarginines with non-natural, un-
charged amino acids [139] led, amongst others, to the pep-
tide (R-Ahx-R)4, in which Ahx represents a six-atom amino-
hexanoic acid spacer. Abes et al. demonstrated that in con-
trast to Tat or oligoargine, PMO-conjugates of this peptide 
led to dose-dependent splice correction at low micromolar 
concentrations in the absence of endosomolytic agents. The 
underlying mechanism for this superior activity is not clear 
yet, as the uptake of (R-Ahx-R)4 constructs was less efficient 
than the uptake of Tat or oligoarginine constructs and also 
involved endocytotic routes [126]. The second peptide is a 
derivative of penetratin, to which six arginine residues were 
added at the N-terminus (R6Pen). R6Pen-PNA conjugates 
were shown to promote efficient splice correction at low 
concentrations and in the absence of endosomolytic agents 
[127]. Again, uptake of R6Pen-conjugates seemed to involve 
endocytosis and there was hardly any difference in splice 
correcting activity regardless of the nature of the linker used 
for conjugation, e.g. a stable thioether versus a reducible 
disulfide linker [130]. 
  Part II of Fig. (3B) illustrates a phenomenon that repre-
sents a strategy for the treatment of Duchenne muscular dys-
trophy (DMD). DMD is a severe progressive neuromuscular 
disorder caused by several different mutations in the dystro-
phin gene that abolish the production of functional protein 
[140]. Depending on the location of the mutation, the corre-
sponding exon is skipped by covering the responsible splice 
sites with steric block oligonucleotides. This allows the tran-
scription of internally deleted, but largely functional, dystro-
phin proteins and converts a severe DMD into a milder 
Becker muscular dystrophy phenotype. A more detailed de-
scription of this approach and its application in a number of 
animal models can be found in several excellent recent re-
views [141,145]. Successful systemic delivery of splice 
switching oligonucleotides with or without chemical modifi-
cations (PMO, LNA, OMe) has been accomplished via injec-
tion of naked nucleic acids [146,147], with the help of viral 
vectors [148], through re-implantation of ex vivo manipu-
lated stem cells [149] or in combination with CPPs [150-
154]. For the latter purpose, several studies were carried out 
with novel derivatives of arginine-rich peptides containing 
different numbers of non- amino acids, e.g. aminohexanoic 
acid and/or -alanine. These CPP-PMO conjugates showed 
higher serum stability, less endosomal trapping and led to 
efficient exon skipping in myoblasts and mice at lower dos-
ages than the splice switching PMO alone [152,153]. Yin et 
al. [154] used a PNA-modified splice-switching oligonucleo-
tide conjugated to Tat, a muscle specific peptide (MSP) or 
different functional domains of the adenovirus capsid protein 
VP1 (AAV6, AAV8) and examined exon skipping efficiency 
in vitro and in vivo. Surprisingly, both after transfection and 
intramuscular injection, the activity of these PNA-peptide 
conjugates was not significantly better than that achieved by 
naked neutral PNA, presumably due to endosomal trapping.  
STRATEGIES FOR QUANTIFICATION 
  Intracellular trafficking represents one of the major limi-
tations of current non-viral nucleic acid delivery approaches 
[155]. In other words a large percentage of intracellular 
cargo molecules are entrapped in vesicular compartments 
and thus will not trigger the desired effect. Moreover, degra-
dation or retrograde transport might further reduce the num-
ber of active molecules. So in order to determine the overall 
efficacy of a given delivery approach it is essential to know 
the numbers of intact cargo molecules inside the cell along 
with the minimal numbers of molecules required to cause a 
particular effect. Based on such information one can easily 
calculate the percentage of bioactive molecules. In the fol-
lowing chapter we will briefly describe selected examples of 
variable suitability for a quantitative determination of nu-
cleic acids in a cellular context. 
  In principle, either the peptide or the cargo can be labeled 
by a reporter group, e.g. a radioisotope [156] or a fluoro-
phore [157]. Fluorescent peptides or cargos have been quan-
titatively evaluated by FACS [54] or fluorescence correlation 
microscopy (FCS) [158] or FRET [159]. In all cases, it is 
crucial to distinguish between internalized and membrane-
associated signals. For this purpose, a simple wash step with 
just buffer is not sufficient to completely remove membrane-
bound peptide/cargo-complexes [54,55]. Extracellularly 
bound complexes can be efficiently removed for example by 
enzymatic digestion with trypsin [160], acid wash [161] or 
heparin treatment [55,162]. Alternatively, discrimination 
between intra- and extracellular material is possible through 
chemical modification of extracellular components [163] or 
fluorescence quenching [164].  
  Having established that only intracellular signals are 
taken into account, it is still challenging to distinguish be-
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studies, a fluorescence-based quantification method was 
combined with either HPLC analysis [163] or “cell activity 
by capillary electrophoresis” [165] to verify the integrity of 
cargo and carrier.  
  Recently, a technique to measure cellular uptake of CPPs 
by matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) was reported by the 
group of Burlina [166-168]. This quantification is based on 
the addition of an internal standard, i.e. a peptide with a sta-
ble isotope label. The method has been used to determine the 
amount and stability of intact internalized peptides, e.g. 
Penetratin, R9 and several novel CPPs, and can also be used 
for the quantification of peptidic cargoes, e.g. an inhibitor of 
protein kinase C [166].  
 Varga  et al. [169-171] developed an “integrative sys-
tems” approach, combining quantitative experiments and 
computational modeling studies of vector uptake and traf-
ficking kinetics, with the aim to take multiple potentially 
rate-limiting cellular and molecular processes into account. 
By applying their mathematical model to plasmid delivery 
with either Lipofectamine, several PEI-based vector formula-
tions or an adenoviral vector, they could successfully predict 
experimentally observed effects and identify endosomal es-
cape as the most important rate-limiting intracellular barrier 
for non-viral vectors. Recently, Zhou et al. [172] applied a 
similar strategy for the characterization of a novel lipopoly- 
mer (WLSP). This carrier shows an increased rate of en-
dosomal escape compared to conventional PEI-based carri-
ers. 
  With the aim to quantify rhodamine-labeled plasmid 
DNA in cellular compartments while avoiding problems 
arising from subcellular fractionation, like recovery and 
leakage, Akita et al. [173] developed a novel quantitative 
strategy, the confocal image-assisted three-dimensionally 
integrated quantification (CIDIQ) method. To distinguish 
endosomes/lysosomes and the nucleus from the cytosol, they 
were stained with LysoSensor DND-189 and Hoechst 33258, 
respectively, and sequential Z-series images were captured 
by CLSM. By applying this quantification method, the 
authors could show that due to a rapid endosomal escape, 
Lipofectamine Plus delivered more plasmid into the nucleus 
than R8 or stearylated R8. Hama et al. [174] used the same 
method in combination with TaqMan PCR to evaluate the 
uptake and intracellular distribution of plasmid DNA after 
delivery with viral as well as non-viral vectors. Due to supe-
rior cell surface binding, the efficiency of cellular uptake 
was significantly higher for Lipofectamine Plus than for 
adenovirus whereas intracellular trafficking, i.e. endosomal 
escape and nuclear transfer, were essentially the same. How-
ever, to achieve comparable transgene expression, 8000-fold 
higher intranuclear plasmid numbers were required in case of 
Lipofectamine Plus. This finding suggests a difference in 
nuclear transcription efficiency after non-viral delivery.  
  In another approach, Jiang et al. [175] extended the 3’ 
end of the sense strand of a siRNA with a nuclease-resistant 
DNA hairpin to obtain a so-called “crook” siRNA. This 
modification had no effect on RNAi-mediated reporter gene 
inhibition and served as a primer for a filling-in reaction fol-
lowed by PCR. Parameters were chosen so that the initial 
rate of template amplification correlates with the initial con-
centration of the “crook” siRNA. Under these conditions, 
quantification of attomolar siRNA levels per cell was possi-
ble after liposomal transfections with Oligofectamine. 
  A highly sensitive method was developed by Overhoff et 
al. [176] for the detection of siRNA after phosphorothioate-
stimulated uptake [177] and adapted for the quantification of 
siRNA or steric block oligonucleotides after non-covalent 
peptide-mediated delivery ([55] and Laufer et al., manuscript 
in preparation, see chapter “MPG-mediated delivery of 
siRNA and steric block oligonucleotides”). This so-called 
liquid hybridization assay is based on the extraction of total 
cellular RNA and the subsequent hybridization in solution of 
a radioactively labeled probe which is complementary to the 
oligonucleotide to be detected. Finally, following PAGE 
analysis, absolute amounts of internalized oligonucleotide 
can be quantified with high accuracy down to ~10 molecules 
per cell using internal standards [55]. In addition to this out-
standing sensitivity, no amplification step is needed and only 
intact oligonucleotides are taken into account.  
MPG-MEDIATED DELIVERY OF siRNA AND 
STERIC BLOCK OLIGONUCLEOTIDES – AN EX-
AMPLE OF A QUANTITATIVE EVALUATION 
 C onsidering the multitude of available CPPs, nucleic 
acid cargos and cellular as well as animal model systems, a 
comparison of different delivery strategies seems nearly im-
possible. In this context, we have for the first time under-
taken a detailed side by side comparison of two different 
model systems using the peptide MPG as delivery agent. In 
the following paragraph we present own experimental data to 
exemplarily illustrate particular aspects regarding current 
limitations of peptide-based delivery systems. In contrast to 
many other CPP procedures, which rely on covalent linkage 
of carrier and cargo, the peptide MPG forms highly stable 
non-covalent complexes with nucleic acids, displaying bind-
ing constants in the low nanomolar range ([55], A. Trampe, 
unpublished data). The high flexibility of this non-covalent 
approach can be exploited to easily transport a wide variety 
of nucleic acid cargos without having to synthesize a new 
construct for each oligonucleotide. We have used MPG for 
the delivery of siRNAs in the context of an RNAi-based re-
porter system and for the delivery of steric block oligonu-
cleotides in the context of the splice correction assay de-
scribed above [121]. After MPG-mediated transfection of a 
luciferase-targeted siRNA, we observed strong inhibition of 
reporter gene readout with an IC50 in the subnanomolar range 
[55]. After MPG-mediated transfection of a luciferase-
targeted steric block oligonucleotide (further on also referred 
to as ON-705), we observed a moderate up-regulation of 
reporter gene readout, representative of low splice correcting 
activity (Laufer et al., manuscript in preparation). One pos-
sible explanation for the different degree of reporter gene 
regulation could be the different intracellular target sites, i.e. 
the cytoplasm for siRNAs and the nucleus for splice correc-
tion oligonucleotides. To attain more information about the 
subcellular localization of MPG-oligonucleotide com-
plexes, we performed confocal laser scanning as well as 
conventional fluorescence microscopy studies with fluores-
cently labeled siRNAs or steric block oligonucleotides. In 
both cases, a punctuate non-homogenous distribution of the 
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indicative of an accumulation of nucleic acids in endocytotic 
vesicles, which was verified by coincubation with LysoSen-
sor (Fig. (4A)). A quantitative computational analysis of 
fluorescence microscopy data yielded an average of ap-
proximately 50 % colocalization between endosomes and 
siRNA (Fig. (4B)). In contrast to earlier assumptions that 
CPPs directly traverse the lipid bilayer, it has commonly 
become accepted that for most peptide-cargo combinations 
endocytosis plays a major role in cellular uptake. As de-
scribed above and in the chapter “Strategies to enhance en-
dosomal escape” below, administration of endosome disrup-
tive substances like chloroquine can greatly increase en-
dosomal release of trapped nucleic acids. Chloroquine is a 
weak base, non-charged at neutral pH but charged at pH 5.5 
[178]. It is able to pass easily through membranes in its un-
charged form, but becomes protonated and accumulates 
within acidic vesicles in its positively charged, membrane-
impermeable form. Although its exact mode of action has 
not yet been resolved, it is generally accepted that chloro-
quine works via prevention of endosome acidification which 
in turn increases the residence time of cargo within the en-
dosomes eventually resulting in a higher probability of trans-
fer to the cytoplasm. Fluorescence microscopy analyses in 
the presence of 100 M chloroquine yielded two quite con-
trary outcomes. While the localization of siRNA did not 
change after addition of chloroquine (Fig. (4C)), for the 
steric block oligonucleotide the picture changed completely 
(Fig. (4D)). In the latter case, a diffuse fluorescence all over 
the cytoplasm with an accumulation of ON-705 in the nu-
cleus could be observed. Nonetheless, considerable amounts 
of nucleic acid molecules were still visible as a punctual pat-
tern, which indicates that the chloroquine treatment liberates 
only a certain fraction. On the whole, these qualitative ob-
servations are in full agreement with the observed biologic 
effects in the absence or presence of chloroquine (Fig. (5A)). 
For MPG-mediated transfection of siRNA, even under 
conditions where the amount of bio-available siRNA was 
severely limited, only a minor increase in RNAi (ca. 30 %) 
was measurable. For MPG-mediated transfection of steric 
block oligonucleotide, on the other hand, a dramatic increase 
of reporter gene up-regulation by a factor of 50 - 100 was 
observed. However, in both cases, the overall uptake did not 
change upon incubation with chloroquine (Fig. (5B)), which 
proves that the endosomolytic substance does not interfere 
with uptake but leads to a re-distribution of internalized nu-
cleic acids. The underlying mechanism for the different ef-
fects triggered by chloroquine in case of peptide/siRNA and 
peptide/steric block oligonucleotide complexes remains un-
clear. Though, this is a good example that the cargo can sub-
stantially affect the properties and thereby intracellular traf-
ficking of a particular carrier system.  
  Ultimately, to assess the overall efficacy of this carrier 
system, we were interested to elucidate which percentage of 
molecules taken up after MPG-mediated delivery is bio-
logically active. To derive such information, the exact intra-
cellular amount of intact oligonucleotide, the corresponding 
reporter signal and the minimal number of molecules neces-
sary to trigger a specific degree of reporter gene modulation 
have to be known. For the quantification of internalized 
cargo, we adapted a highly sensitive method first described 
by Overhoff et al. [176], enabling us to detect intracellular 
oligonucleotide amounts down to  10 copies per cell [55]. 
The method is based on the liquid hybridization of a radioac-
tively labeled probe with the corresponding oligonucleotide 
in cellular lysates. In this context it should be noted that a 
stringent heparin wash following the transfection procedure 
is crucial to avoid an overestimation of intracellular nucleic 
acid molecules due to complexes attached to the outside of 
the cell membrane [54,55]. In order to correlate the numbers 
derived from the quantification experiments with the mini-
mal number of molecules essential to trigger the observed 
effect, an independent assay had to be established. The gold 
standard in this case is microinjection as this technique en-
ables one to deliver definite amounts of nucleic acids with a 
high degree of bioavailability into the cytoplasm or the nu-
cleus of a mammalian cell along with a low toxicity profile 
and great accuracy. Considering that after cytoplasmic mi-
croinjection only 12 siRNA molecules are sufficient for half-
maximal inhibition of reporter gene expression, one can es-
timate that of the 10,000 molecules measured after MPG-
mediated transfection, only ca. 0.1 % are biologically active 
(Table 4). For the splice correction assay, the numbers are 
different in terms of absolute numbers but the outcome re-
mains the same. Compared to the 300,000 molecules suffi-
cient for maximal splice correction after nuclear microinjec-
tion, of the 70,000,000 molecules required following pep-
tide-mediated delivery only ca. 0.5 % are biologically active 
(Table 5). In both cases >> 99 % of internalized oligonucleo-
tides are most likely retained in endosomes and subsequently 
degraded in lysosomes after peptide-mediated delivery. 
Frankly, this is a sobering result and puts in numbers how 
much room for improvement there actually is. Though it 
certainly is not legitimate to generalize these findings, there 
are countless reports in the literature suggesting similar limi-
tations for the majority of non-viral strategies.  
  According to actual conceptions, siRNA enters a multi-
ple-turnover pathway with one siRNA molecule capable of 
RISC-mediated cleavage of 50 or more mRNA molecules 
[79]. Even though the fate of steric block oligonucleotides is 
not really clear, it can be assumed that per splicing event one 
molecule is used up and translated into a functional mRNA 
molecule (e.g. single-turnover pathway). As a result the 
number of molecules needed to trigger an apparent effect is 
much higher in the splice correction assay compared to the 
RNAi-based reporter system (confer Table 4 and Table 5). 
On the other hand, being a single-turnover pathway, the 
splice correction assay should be much more sensitive to 
even minor changes in intracellular steric block oligonucleo-
tide concentrations whereas the catalytic nature of the multi-
ple-turnover RNAi mechanism might mask such small varia-
tions. This is in accordance with the data described above.  
  Taken together, based on the results presented as well as 
unpublished data (Laufer et al., manuscript in preparation), 
the splice correction assay appears to be the superior tool for 
a quantitative assessment of nucleic acid delivery strategies. 
STRATEGIES TO ENHANCE ENDOSOMAL ESCAPE 
  As outlined above, endosomal release is one of the major 
rate-limiting steps for cellular delivery of macromolecules 
via cationic lipids, polyplexes and especially CPPs. In the 
following chapter we will present some examples of how to 
increase endosomal release. Peptide-Mediated Cellular Delivery of Oligonucleotide-Based Therapeutics  Current Pharmaceutical Design, 2008, Vol. 14, No. 34    3647 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Confocal (A) and semiconfocal (C and D) microscopic analyses of intracellular RNA localization following peptide-mediated 
transfection. (A) Living ECV304 cells were transfected for 4 h with 4.2 M MPG and 10 nM Cy3-labeled siRNA. Subsequently cells were 
incubated with 5 μM LysoSensor (Invitrogen). (I) Overlay of the phase contrast image with all fluorescence channels, (II) Cy3-channel 
(siRNA - red), (III) LysoSensor channel (green) and (IV) overlay of red and green channel. Yellow dots indicate colocalization. (B) Quantita-
tive analysis of siRNA/LysoSensor colocalization using the program ImageJ. For each data point 5 cells were analyzed and averaged. (C) 
Living ECV-GFP-Nuc cells [55] were transfected for 4 h with 4.2 M MPG and 10 nM Cy3-labeled siRNA in the absence and presence of 
100 M chloroquine (CQ).The left images show the red (siRNA) channels followed by an overlay of the red and green (nuclei) channels. The 
right panel shows plots of the intensity profiles for the green channel and the Cy3-channel along the line indicated in the figure to the left. (D) 
Living HeLa Luc/705 cells were transfected for 4 h with 2.5 M MPG and 278 nM Cy3-labeled ON-705 PTO in the absence and presence 
of 100 M chloroquine (CQ). The very left images show an overlay of the phase contrast with all fluorescence channels followed by the red 
(steric block) and an overlay of the red and blue (nuclei) channels. The right panel shows plots of the intensity profiles for the DAPI-channel 
(blue) and the Cy3-channel (red) along the line indicated in the figure to the left. Cell nuclei are either stained via GFP-Nuc (green) or with 
DAPI (blue). 3648    Current Pharmaceutical Design, 2008, Vol. 14, No. 34  Laufer and Restle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Influence of chloroquine on MPG-mediated delivery of siRNA and steric block oligonucleotide. Cells were transfected with 
complexes of 2.1 M MPG and 1 nM siRNA or 2.5 M MPG and 278 nM steric block oligonucleotide either in the presence or absence of 
100 M chloroquine (CQ). 24 h later, RNA interference and splice correction were measured via reporter gene activity (A) and uptake was 
determined using the liquid hybridization protocol [55] (B). The factor of enhancement was calculated from three independent experiments 
based on the situation without CQ.  
 
Table 4.  Summary of Quantitative Studies Concerning Peptide-Mediated siRNA Uptake  
Mode of Delivery  Molecules Per Cell for Half-Maximal Inhibition 
LF2000-mediated transfection  ~300 
MPG-mediated transfection  ~10,000 
cytoplasmic microinjection  ~12 
Transfections were performed with 2.1 M MPG and 1 nM siRNA or 10 g/ml LF2000 and 0.02 nM siRNA, i.e. in the range of the IC50 value [55]. Quantification was performed 
after 24 h according to the liquid hybridization protocol [55]. Molecules per cell were calculated based on the cell number seeded for transfection. For microinjection experiments, 
molecules per cell were calculated on the basis of the injection volume. 
 
Table 5.  Summary of Quantitative Studies Concerning Peptide-Mediated Steric Block Oligonucleotide Uptake 
Mode of Delivery  Molecules Per Cell for Maximal Splice Correction 
LF2000-mediated transfection  ~7,000,000 
MPG-mediated transfection  ~70,000,000 
nuclear microinjection  ~300,000 
Transfections were performed with 2.5 M MPG or 7 g/ml LF2000 and 278 nM steric block oligonucleotide, respectively, to achieve maximal splice correction. Quantification 
was performed after 24 h according to the liquid hybridization protocol ([55] and Laufer et al., manuscript in preparation). Molecules per cell were calculated based on the cell num-
ber seeded for transfection. For microinjection experiments, molecules per cell were calculated on the basis of the injection volume. 
 
  Endosome-disrupting substances, like chloroquine, cal-
cium or sucrose, were used to significantly enhance the ac-
tivity of antisense PNA oligonucleotides conjugated to Tat, 
oligoarginines or oligolysines [125,179,180]. This effect did 
not result from increased uptake, but rather improved 
bioavailability in the cytoplasm or nucleus after endosomal 
escape. Takeuchi et al. [181] showed that by incubation of 
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peptides could be shifted from endocytic uptake to direct 
membrane translocation, yielding a rapid distribution of the 
peptide throughout the cytoplasm, even at 4 °C. Pyrenebu-
tyrate acts as a counteranion and, by interacting with the 
positively charged peptide, increases the overall hydropho-
bicity, thereby facilitating a direct translocation through the 
lipid bilayer, as earlier shown with artificial membranes 
[182]. This method, which works only in the absence of a 
medium or serum, was successfully applied for administra-
tion of a fluorescent protein and an apoptosis-inducing pep-
tide into dividing as well as non-dividing cells [181]. How-
ever, in general the strategies described above are not feasi-
ble for in vivo applications, due to high cytotoxicity or other 
undesirable secondary effects. 
  The imidazole group of histidine (His) can absorb pro-
tons in the acidic environment of the endosome, leading to 
osmotic swelling, membrane disruption and eventually nu-
cleic acid escape. Accordingly, Lo et al. [183] modified Tat, 
which can bind and condense DNA through ionic interac-
tions but has no acidic residues that can promote endosomal 
release, with different numbers of His residues. Highest re-
porter gene expression could be achieved after plasmid de-
livery with a Tat peptide covalently fused to 10 His residues 
(Tat-10H). Insertion of two additional cysteine residues into 
Tat-10H further enhanced stability of peptide/DNA com-
plexes and transgene expression through formation of inter-
peptide disulfide bonds. Youngblood et al. [184] evaluated 
the influence of the stability of arginine-rich peptide PMO 
conjugates on cellular uptake and antisense activity. They 
could show that the stability is affected by the amino acid 
composition and the type of linkage to the cargo. Moreover, 
they found that degraded fragments could not escape any-
more from endosomal or lysosomal compartments.  
  Another concept makes use of photosensitive substances, 
which induce the release of macromolecules from vesicles 
by light exposure. This so-called photochemical internaliza-
tion (PCI) has, in the past, been used for intracellular deliv-
ery of a large variety of macromolecules (reviewed in [185]) 
and, more recently, for the endosomal release of nucleic ac-
ids after delivery mediated by liposomes [186,187], poly-
plexes [188] or CPPs [138,189]. Shiraishi et al. [138] inves-
tigated the biological activity of PNAs conjugated either to 
Tat, R7 or KLA-peptide in combination with a PCI treat-
ment. Depending on the peptide, nuclear as well as cytosolic 
antisense effects could be enhanced by up to two orders of 
magnitude. Similar results were presented by Folini et al. 
[189] for a PNA targeting human telomerase reverse tran-
scriptase conjugated to Tat. In both studies, lower nucleic 
acid doses were sufficient, thereby reducing the probability 
of off-target effects. In light of encouraging data from ongo-
ing anticancer clinical trials employing photodynamic ther-
apy [190,191], an in vivo application of PCI seems feasible 
and will be discussed in more detail by Oliveira et al. [192] 
in this issue. Furthermore, target specificity could be in-
creased by local illumination of cells or tissue. 
  Viral fusion proteins drive the fusion process between the 
viral membrane and the endosomal host cell membrane in a 
pH-dependent manner, which is required to translocate the 
viral genome into the cytoplasm after receptor-mediated en-
docytosis. Fusogenic peptides, usually hydrophobic, rich in 
glycine residues and found at the amino terminus of these 
proteins, were shown to have membrane perturbing and lipid 
mixing activities [193]. Many well studied representatives of 
this group are derived from the fusion sequence of influenza 
virus HA or HIV-1 gp41 [194] and have been used to im-
prove the transfection efficiency of non-viral delivery sys-
tems [195].  
  Addition of the influenza-derived dimeric peptide diINF-
7 to LF2000/siRNA complexes had no effect on the particle 
size of ca. 120 nm, but significantly improved gene silencing 
activity of siRNAs targeting the epidermal growth factor 
receptor or the K-ras oncogene [196]. Similar results were 
obtained for plasmid delivery through addition of a fu-
sogenic peptide derived from herpes simplex virus glycopro-
tein H to Lipofectamine/DNA complexes [197]. To the same 
end, Futaki et al. [198] used the peptide GALA, which was 
specially designed to mimic the function of viral fusion se-
quences, together with various commercially available cati-
onic liposomes. Although they could not detect significant 
differences in cellular localization, plasmid transfection effi-
ciency was increased and liposomal dosage could be re-
duced. 
  PEI covalently modified with the HIV-1 gp41-derived 
peptide HGP led to a 38-fold increase of gene expression 
after plasmid DNA delivery and also enhanced siRNA-
mediated knockdown of GAPDH by approximately 2-fold 
[199]. 30 % of cells incubated with PEI-HGP polyplexes 
showed not only the punctuate plasmid DNA staining ob-
served with PEI polyplexes alone, but also a diffuse fluores-
cence throughout the cell, indicative of endosomal release of 
vectors. This would explain the observed increase in trans-
fection efficiency, since the overall uptake was unaffected. 
 Wadia  et al. [62] were the first to use the influenza he-
magglutinin-derived fusogenic peptide HA2 in combination 
with a CPP. Delivery of a Tat-HA2 conjugate with increas-
ing concentrations of a Tat-Cre conjugate enhanced reporter 
protein activity, presumably through an increased release 
from macropinosomes. The same fusogenic peptide, linked 
to a polyarginine-p53 conjugate, promoted release of p53 
from macropinosomes and subsequent translocation to the 
nucleus, accompanied by an enhanced anti-cancer effect 
[200]. 
CONCLUSIONS AND FUTURE PROSPECTS 
  The development of delivery systems for therapeutic oli-
gonucleotides is a fast growing field. Owing to the enormous 
potential of short nucleic acids as alternative drugs such a 
growth is not unexpected. Besides viral vectors there is a 
highly diverse and constantly increasing number of non-viral 
systems evolving. However, despite considerable progress 
achieved in recent years, even the most advanced systems 
either lack the efficiencies required for downstream drug 
development or do show a substantial degree of toxicity or 
both. Of the many factors which limit their use, cellular up-
take of the cargo/carrier complexes and subsequent intracel-
lular trafficking to reach the target site are the most impor-
tant. In addition to such essential considerations there are 
various additional parameters to be taken into account like 
serum stability, pharmacokinetic features and tissue barriers 
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  Now the question arises where to start optimizing a given 
delivery system. Currently, there is a clear trend towards in 
vivo testing. In principle such a development is a step in the 
right direction since many of the experimental data derived 
from artificial cell tissue culture systems with established 
cell lines are not applicable to the in vivo situation. On the 
other hand, it is questionable to what extent such animal ex-
periments will eventually pay off as long as important fun-
damental problems remain largely unsolved. As outlined 
above, our quantitative studies along with microscopic 
analyses of siRNAs and steric block oligonucleotides using 
either a peptide or a commercially availably cationic lipid as 
carrier clearly show that less than 0.1% - 5% of molecules 
taken up are involved in a biological response, i.e. RNAi-
mediated down regulation or splice correction-mediated up 
regulation of reporter gene activity. Evidently, the vast ma-
jority of internalized cargo never reaches the target. This 
implies that uptake per se is not the limiting factor here. Al-
though there are no such detailed quantitative numbers avail-
able in the literature for other systems, there are countless 
reports showing that to various degrees this applies to almost 
any non-viral delivery approach currently available. Taken 
together, if one would succeed to optimize intracellular traf-
ficking this holds the potential to boost overall efficacy by 
up to 3 orders of magnitude. Moreover, it is reasonable to 
assume that such fundamental cellular restrictions can be 
adequately investigated in tissue culture without the use of 
animal models. So it might be worthwhile to reconsider the 
concept of maybe premature in vivo testing by moving 
backwards one step and first optimizing the systems with 
regard to intracellular limitations before dealing with the 
next level of complexity. Accordingly, in vitro model sys-
tems like the ones described above for siRNAs or steric 
block oligonucleotides are valuable tools to study particular 
aspects of nucleic acid delivery. However, currently avail-
able data are based on studies using a variety of different cell 
lines and techniques, which renders a direct comparison of 
different delivery approaches impossible. In this context it 
would be highly desirable to introduce standardized proto-
cols for in vitro testing (e.g. the splice correction system de-
veloped by Kole and coworkers [121]) together with meth-
ods for detailed quantitative analyses (e.g. the liquid hybridi-
zation protocol [55,176]). This would facilitate a direct quan-
titative comparison of exceedingly diverse approaches on at 
least the cellular level.  
  One reason for the problem with intracellular trafficking 
of oligonucleotides arises from the mode carrier/cargo com-
plexes are taken up by cells. Today it is well established that 
the majority of these complexes are taken up via endosomal 
pathways and therefore end up in vesicular compartments 
from which they have to escape in order to reach their target. 
Although there are many attempts reported to trigger en-
dosomal escape by various strategies, they either proved to 
be toxic or did not achieve sustained success. Additionally, 
there might be a further reason for the encountered difficul-
ties to overcome these intracellular barriers. It is not unrea-
sonable to speculate that during evolution cells might have 
evolved mechanisms to avoid large amounts of foreign nu-
cleic acids freely floating in the cytoplasm and thus safely 
contain them in vesicular compartments where they are 
eventually degraded. Alternatively they might be exported 
by retrograde transport. Co-evoluting viruses evidently have 
developed strategies to circumvent such defense mecha-
nisms. So it might be somewhat naive to expect that a rather 
simple man-made carrier system is capable to efficiently 
overcome such an intrinsic barrier. Current developments 
towards more complex and elaborate carrier systems take 
into account such considerations. In any case it appears there 
is no simple solution for this problem.  
  In conclusion, despite significant progress in the field of 
nucleic acid delivery in vitro as well as in vivo, there still is a 
long way to go before this will become a standard procedure 
in the clinic. Certain problems like endosomal escape are 
known for more than twenty years and still far from being 
resolved. In order to develop new strategies, more informa-
tion about intracellular processes involved in nucleic acid 
trafficking is needed. Moreover, it would be desirable if the 
field would move from a qualitative description towards a 
quantitative evaluation preferentially using standardized 
model systems. This would allow for comparison of different 
approaches with one another. While animal studies are inevi-
table in the long run, there still is a lot of room for improve-
ment on the cellular level. So it might be worthwhile to 
fathom how far we can push the different systems on this 
level.  
ACKNOWLEDGEMENTS 
  We apologize to those authors whose work was not cited 
directly owing to space limitations. We thank Alexander 
Trampe for microscopic images, Anna Lena Recke, Sandra 
Veldhoen, Georg Sczakiel and members of his group for 
fruitful discussions, Silke Degen for critically reading the 
manuscript and our co-workers in the EC project ’Peptides in 
Drug Delivery’, Annette G. Beck-Sickinger, Ernest Giralt, 
Fréderic Heitz, Christian LeGrimellec and Hans-Peter 
Merkle for constructive collaborations. T.R. acknowledges 
funding by EC-grants QLK2-2001-01451 and LSHG-CT-
2003-503480. 
ABBREVIATIONS  
AchR =  Acetylcholine  receptor 
bPrPp  =  Bovine prion protein derived peptide 
CLSM  =  Confocal laser scanning microscopy 
CPP =  Cell-penetrating  peptide 
CQ =  Chloroquine 
DMD =  Duchenne  muscular  dystrophy 
FACS  =  Fluorescence assisted cell sorting 
FCS =  Fluorescence  correlation  spectroscopy 
GFP  =  Green fluorescent protein 
gp41 =  Glycoprotein  41 
HA =  Hemagglutinin 
HIV =  Human  immunodeficiency  virus 
IL =  Interleukin 
IFN =  Interferon 
JEV =  Japanese  encephalitis  virus Peptide-Mediated Cellular Delivery of Oligonucleotide-Based Therapeutics  Current Pharmaceutical Design, 2008, Vol. 14, No. 34    3651 
LF =  Lipofectamine™ 
LF2000 =  Lipofectamine™  2000 
MALDI- =  Matrix-assisted  laser  desorption/ionization 
TOF MS    time-of-flight mass spectrometry 
MAP =  Model  amphipathic  peptide 
MEND  =  Multifunctional envelope-type nano device 
NLS =  Nuclear  localization  sequence 
OMe =  2’-O-Methyl 
PCI =  Photochemical  internalization 
PEG =  Polyethylene  glycol 
PEI =  Polyethyleneimine 
PMO  =  Phosphorodiamidate morpholino oligomer 
PNA =  Peptide  nucleic  acid 
POD  =  Peptide for ocular delivery 
PTD  =  Protein transduction domains 
PTGS  =  Post-transcriptional gene silencing 
RBD =  RNA-binding  domain 
RNAi =  RNA  interference 
RVG  =  Rabies virus glycoprotein 
siRNA =  Small  interfering  RNA 
shRNA =  Short  hairpin  RNA 
STR-R8 = Stearyl-R8 
TFO  =  Triplex forming oligonucleotide 
TNF  =  Tumour necrosis factor 
TP10 =  Transportan  10 
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